Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN

Imogen Caldwella Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, AustraliaCorrespondence[email protected]

David Byrnea Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia

Stephen Ladea Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia

Tim Akhurstb Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia

Adrian Minsonc Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

Michael Dickinsonc Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia

Ella Thompsona Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia

Clare Scottd Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia;e The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia;f Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Piers Blomberya Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia;c Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to acknowledge funding from the Stafford Fox Medical Research Foundation, the Snowdome Foundation and the Wilson Centre for lymphoma genomics.

IC is a recipient of the Mike and Carole Ralston Traveling Fellowship (2020) from the RCPA Foundation.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN

Information for

Open access

Opportunities

Help and information

Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN

Acknowledgements

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature